Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Pre-NDA Work Takes Added Importance As PDUFA V Stretches Review Cycle

You may also be interested in...



PDUFA Communications Hurt By Sequestration As Late-Stage Meetings Begin

Twenty sponsors now have applications in the new review model, but none have reached the approval decision stage; industry officials say it still is too early to draw conclusions.

Maximizing PDUFA V Meeting Opportunities Requires Work By Sponsors

To get the most out of formal interactions with the agency, sponsors must prepare thoroughly and listen for FDA “regulatory speak,” agency and industry representatives advise.

Late-Cycle Approval Predictions Not A Good Idea, FDA Says

OND Director John Jenkins says the late-cycle meeting in the new PDUFA review model will offer a lot of information to sponsors, but likely will not be predictive of application approvability.

Related Content

Topics

UsernamePublicRestriction

Register

PS053383

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel